CLASP1 and neoplasm: In their experiment, clinical endpoints like overall survival, disease-free survival, tumor response to chemotherapy are not confirmed by validation either on the same group or on the independent group of patients, just CLASP1 gene with BRCA1 mutation status related to one ovarian cancer subclass which tend to deteriorate easily.